mTOR signaling in growth control and disease
What this study shows
The classic 2012 Cell review that became the standard reference for mTOR signaling. Comprehensive yet readable synthesis of how mTOR integrates environmental cues to control growth, and how its deregulation drives cancer, obesity, diabetes and neurodegeneration. A perfect companion to the newer 2020 review.
At a glance
| Evidence type | R Review — secondary literature, not a new result Marked R because it is a review or synthesis of existing evidence rather than a new primary result; that is a different form of writing, not a weaker one. |
| Study type | Narrative Review |
| Model system | Review (comprehensive) |
| Journal | Cell |
| Year | 2012 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.1016/j.cell.2012.03.017 · PMID 22500797 · Free full text (PMC3331679) |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | Not applicable (review) |
| Target | mTORC1 / mTORC2 |
| Model | Review |
| Effect | Comprehensive review of mTOR signaling in growth control and disease (cancer, obesity, diabetes, neurodegeneration) |
In the Atlas
Related topics
More studies on this topic
- mTOR at the nexus of nutrition, growth, ageing and disease (2020)
- Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression (2013)
- Lysosomal mTORC2/PHLPP1/Akt regulate chaperone-mediated autophagy (2015)
- mTOR substrate phosphorylation in growth control (2022)
Was this page useful?
Thank you. Your answer was counted anonymously.